You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国抗体(03681.HK)与D2M订立创新型靶点药合作协议
阿思达克 07-23 04:18
中国抗体-B(03681.HK)公布,与D2M订立有关创新型药物靶点识别的合作协议,公司有权根据优先靶点选择机制对公司从D2M靶点识别工作的原始结果中选择的合格药物靶点进行後续研究、发展及商业化;D2M须为公司物色创新型药物靶点,以评估有关发现的科学及商业价值初步为期三年。同时,公司将以500万美元购买D2M 2,778万股优先股,持股38.17%。

D2M是一家专门开发基因驱动靶点识别平台,以及就治疗或预防人类疾病针对该等靶点发现、发展及商业化疗法及治疗的公司。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account